Literature DB >> 26271067

Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence.

Gilles Montalescot1, David Brieger2, Anthony J Dalby3, Seung-Jung Park4, Roxana Mehran5.   

Abstract

The duration of dual antiplatelet therapy (DAPT) after coronary stenting has been evaluated in randomized studies with apparently conflicting results. Although longer exposure associates with more bleeding complications, late stent thrombosis (ST) and myocardial infarction are reduced. In addition, as new drug-eluting stents carry a lower risk of ST compared with the first-generation drug-eluting stents and possibly even bare-metal stents, a shift toward better protection from ST may have an effect on the duration and intensity of DAPT. Whether the duration of DAPT should be shorter or longer than the currently recommended 6 to 12 months is analyzed in this review, drawing on lessons from the most recent studies.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  P2Y(12) inhibitors; antiplatelet therapy; aspirin; coronary stent; drug-eluting stent

Mesh:

Substances:

Year:  2015        PMID: 26271067     DOI: 10.1016/j.jacc.2015.05.053

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  21 in total

1.  Time for science to catch up with clinical practice?

Authors:  Sara Ariotti; Giuseppe Gargiulo; Stephan Windecker; Marco Valgimigli
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

Review 2.  Role of Gender in Dual Antiplatelet Therapy After Acute Coronary Syndrome.

Authors:  Jaya Mallidi; Kusum Lata
Journal:  Curr Atheroscler Rep       Date:  2019-06-22       Impact factor: 5.113

3.  Long-term dual antiplatelet therapy and concomitant optimal medical therapy following percutaneous coronary intervention.

Authors:  Giuseppe Gargiulo; Marco Valgimigli
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

4.  Translation from the data of clinical trials to precision medicine: limitation of the current risk score for predicting coronary thrombosis and major bleeding.

Authors:  Jong-Hwa Ahn; Jeong Yoon Jang; Young-Hoon Jeong
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 5.  Single or dual antiplatelet therapy after PCI.

Authors:  Yosuke Miyazaki; Pannipa Suwannasom; Yohei Sotomi; Mohammad Abdelghani; Karthik Tummala; Yuki Katagiri; Taku Asano; Erhan Tenekecioglu; Yaping Zeng; Rafael Cavalcante; Carlos Collet; Yoshinobu Onuma; Patrick W Serruys
Journal:  Nat Rev Cardiol       Date:  2017-02-09       Impact factor: 32.419

6.  Long-term performance of the second-generation cobalt-chromium sirolimus-eluting stents in real-world clinical practice: 3-year clinical outcomes from the prospective multicenter FOCUS registry.

Authors:  Feng Zhang; Ji'e Yang; Juying Qian; Lei Ge; Jun Zhou; Junbo Ge
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

7.  Lights and shadows of long-term dual antiplatelet therapy in "real life" clinical scenarios.

Authors:  Marino Scherillo; Plinio Cirillo; Dario Formigli; Giulio Bonzani; Paolo Calabrò; Paolo Capogrosso; Pio Caso; Giovanni Esposito; Rosario Farina; Paolo Golino; Tonino Lanzillo; Franco Mascia; Ciro Mauro; Federico Piscione; Girolamo Sibilio; Bernardino Tuccillo; Bruno Villari; Bruno Trimarco
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

8.  Shedding blood: anemia and adverse events after percutaneous coronary intervention (PCI).

Authors:  Keyvan Karimi Galougahi; Dimitri Karmpaliotis; Ajay J Kirtane; Ziad A Ali
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

Review 9.  Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease.

Authors:  Sara Ariotti; Giuseppe Gargiulo; Marco Valgimigli
Journal:  Curr Cardiol Rep       Date:  2017-01       Impact factor: 2.931

Review 10.  Diabetes and antiplatelet therapy: from bench to bedside.

Authors:  Jose R Rivas Rios; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.